ea0070aep676 | Pituitary and Neuroendocrinology | ECE2020
Martel-Duguech Luciana
, Screen Nik
, Jorgensen Jens Otto L
, Korbonits Marta
, Johannsson Gudmundur
, Webb Susan M
Background: Current guidelines recommend that susceptible patients should be tested and treated for AGHD. Still, it is not universally recognised as a distinct entity and reimbursement of GH replacement therapy is not available in some countries.Aim: 1) to record current practice of AGHD management throughout Europe and benchmark it against existing guidelines, 2) to evaluate educational status of health care professionals.Patients...